Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2341MR)

This product GTTS-WQ2341MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2341MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15775MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ13201MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ3770MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ2158MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ14891MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4543MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ2573MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ13930MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW